Vytorin Related Published Studies
Well-designed clinical trials related to Vytorin (Ezetimibe)
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered
with extended-release niacin in hyperlipidemic patients. [2013]
The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet
and inflammatory biomarkers in patients with metabolic syndrome. [2013]
A comparison of efficacy and safety of an ezetimibe/simvastatin combination
compared with other intensified lipid-lowering treatment strategies in diabetic
patients with symptomatic cardiovascular disease. [2013]
Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease. [2011.06]
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. [2011.05]
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus
rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. [2011]
Achievement of recommended lipid and lipoprotein levels with combined
ezetimibe/statin therapy versus statin alone in patients with and without
diabetes. [2011]
Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. [2010.11.04]
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults >/=65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). [2010.11.01]
Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients. [2010.07]
Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism. [2010.06]
Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). [2010.05.21]
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. [2010.05]
Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. [2010.04]
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. [2010.02.15]
Ezetimibe + simvastatin versus doubling the dose of simvastatin in high
cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). [2010]
Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease
patients. [2010]
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and
rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of
achievement of Joint British Societies (JBS-2) cholesterol targets. [2010]
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. [2009.12]
Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. [2009.10]
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. [2009.09]
The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. [2009.07]
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). [2009.06.15]
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. [2009.04]
Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event. [2009]
Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial. [2008.07]
Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. [2008.05]
Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. [2008.04.22]
Simvastatin with or without ezetimibe in familial hypercholesterolemia. [2008.04.03]
Left atrial volume in patients with asymptomatic aortic valve stenosis (the Simvastatin and Ezetimibe in Aortic Stenosis study). [2008.04.01]
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. [2008.03]
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. [2008.01]
The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. [2007.12]
Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. [2007.08.28]
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. [2007.07]
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). [2007.06]
Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. [2007.04.01]
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. [2007.04]
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? [2007.03.13]
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). [2007.03.01]
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. [2007.02]
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. [2006.12]
The lipid-lowering effect of ezetimibe in pure vegetarians. [2006.12]
Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. [2006.11]
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. [2006.10]
Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. [2006.09]
Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. [2006.09]
Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. [2006.05]
Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. [2006.05]
Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. [2006.05]
Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. [2006.04.18]
Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. [2006.04]
Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. [2006.03]
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. [2006.03]
Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects. [2006.02]
Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. [2005.12]
The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. [2005.08]
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD. [2005.07.14]
Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. [2005.07.10]
Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. [2005.07]
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. [2005.06]
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. [2005.05.10]
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. [2005.05]
Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. [2005.05]
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. [2005.05]
LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. [2005.04]
Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. [2005.04]
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. [2005.03]
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. [2005.02]
Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. [2005.02]
Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. [2005.01]
A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. [2004.11]
Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. [2004.09]
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. [2004.09]
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. [2004.09]
Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. [2004.09]
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. [2004.08]
Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. [2004.08]
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. [2004.07]
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. [2004.06.15]
Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. [2004.06.15]
Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. [2004.06]
Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. [2004.05]
Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. [2004.03.02]
Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. [2004]
Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. [2003.12.15]
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. [2003.06]
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. [2003.05.20]
Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. [2003.04]
Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. [2003.04]
Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. [2003.02.15]
Ezetimibe. [2003]
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. [2002.12.18]
Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. [2002.11.15]
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. [2002.11.15]
Inhibition of intestinal cholesterol absorption by ezetimibe in humans. [2002.10.08]
Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. [2002.09]
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. [2002.05.28]
The plasma concentration and LDL-C relationship in patients receiving ezetimibe. [2001.09]
Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. [2001.08]
A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. [2001.06]
|